Wegovy CVS Deal: Hybrid Market Access Strategy ...

By Rene Pretorius

May 5, 2025

The CVS-Novo Nordisk Wegovy deal, announced in May 2025, epitomizes a hybrid market access strategy aimed at the in the $150 billion USA obesity drug market. Novo Nordisk secured preferred CVS Caremark formulary status and will be off...
Empowering Health: The Role of Self-Care and NCDs in Global Health Policy
Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure
Journavx for Pain Management: Toward Affordability and Access
Defunding Scientific Research: Implications and Misconceptions in GawandeR...
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Cost-Effective HIV PrEP: CAB-LA Transforms Prevention
Global Health Limitations: A Critical Assessment of Structural Constraints an...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries